Early real-world outcomes of aflibercept 8 mg in previously treated neovascular age-related macular degeneration
- 14 April 2026
- journal article
- Published by Springer Nature in Eye
- Vol. 40 (9) , 1351-1357
Abstract
Real-world evidence of aflibercept 8 mg in treatment-experienced patients remains limited. This study evaluated early outcomes of switching treatment-refractory patients with neovascular age-related macular degeneration (nAMD) to aflibercept 8 mg. This retrospective cohort study analysed previously-treated patients who switched to aflibercept 8 mg between January and June 2025. Best-corrected visual acuity (BCVA), central macular thickness (CMT), pigment epithelial detachment (PED) height, macular fluid status and treatment intervals were evaluated at baseline, 3 months, 6 months and final visit. 58 patients (66 eyes) were included. Patients received a mean 24.98 ± 18.04 anti-VEGF injections per eye over 49.41 ± 35.74 months pre-switch. Mean 5.15 ± 1.51 aflibercept 8 mg injections were administered per eye over a mean follow-up period of 25.86 ± 8.34 weeks. Median treatment intervals increased significantly from baseline to final visit (4 to 6 weeks, p < 0.001). 23 eyes (34.8%) achieved ≥8-week intervals by final follow-up. Median BCVA remained stable (70 ETDRS letters, interquartile range [IQR] 62-76 baseline and final follow-up, p = 0.571), as did median CMT (230.5 μm (IQR 189.5-281.2) at baseline to 226.5 μm (IQR 195-257) at final follow-up, p = 0.494). Median PED height showed a significant reduction (175 μm (IQR 106-287) at baseline to 173 μm (IQR 105-251) at final follow-up, p = 0.045). Complete macular fluid resolution occurred in 23.9% of eyes with baseline fluid at the final visit. No serious ocular adverse events occurred in this cohort. Aflibercept 8 mg demonstrated modest interval extension with stable functional and anatomical outcomes in heavily pre-treated nAMD patients. Long-term studies are needed to establish durability.Keywords
This publication has 18 references indexed in Scilit:
- Initial Functional and Anatomical Outcomes of High-dose Aflibercept 8 mg in Exudative Neovascular Age-related Macular DegenerationOphthalmology Retina, 2025
- Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degenerationJapanese Journal of Ophthalmology, 2024
- Real-World 1-Year Outcomes of Treatment-Intensive Neovascular Age-Related Macular Degeneration Switched to FaricimabOphthalmology Retina, 2024
- Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapyEye, 2024
- Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trialThe Lancet, 2024
- Age-Related Macular DegenerationJAMA, 2024
- Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular DegenerationJAMA Ophthalmology, 2023
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trialsThe Lancet, 2022
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisThe Lancet Global Health, 2014
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012